Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | - SEK | -100.0% |
| 2022 | 251 Thousand SEK | -52.01% |
| 2021 | 523 Thousand SEK | -61.74% |
| 2020 | 1.36 Million SEK | 78.46% |
| 2019 | 766 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | 0.0% |
| 2023 Q1 | 182 Thousand SEK | -27.49% |
| 2023 Q3 | 42 Thousand SEK | -59.22% |
| 2023 Q2 | 103 Thousand SEK | -43.41% |
| 2023 Q4 | - SEK | -100.0% |
| 2023 FY | - SEK | -100.0% |
| 2022 Q4 | 251 Thousand SEK | -23.71% |
| 2022 Q2 | 379 Thousand SEK | -15.4% |
| 2022 Q1 | 448 Thousand SEK | -14.34% |
| 2022 FY | 251 Thousand SEK | -52.01% |
| 2022 Q3 | 329 Thousand SEK | -13.19% |
| 2021 Q1 | 1.08 Million SEK | -20.92% |
| 2021 FY | 523 Thousand SEK | -61.74% |
| 2021 Q2 | 881 Thousand SEK | -18.5% |
| 2021 Q3 | 989 Thousand SEK | 12.26% |
| 2021 Q4 | 523 Thousand SEK | -47.12% |
| 2020 Q1 | 1.79 Million SEK | 134.73% |
| 2020 FY | 1.36 Million SEK | 78.46% |
| 2020 Q2 | 1.59 Million SEK | -11.35% |
| 2020 Q3 | 1.39 Million SEK | -12.23% |
| 2020 Q4 | 1.36 Million SEK | -2.29% |
| 2019 Q4 | 766 Thousand SEK | -33.62% |
| 2019 FY | 766 Thousand SEK | 0.0% |
| 2019 Q3 | 1.15 Million SEK | -24.77% |
| 2019 Q2 | 1.53 Million SEK | -13.14% |
| 2019 Q1 | 1.76 Million SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | -100.0% |
| 2016 Q3 | 8.95 Million SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ADDvise Group AB (publ) | 1.61 Billion SEK | 100.0% |
| ADDvise Group AB (publ) | 1.61 Billion SEK | 100.0% |
| Arcoma AB | 3.87 Million SEK | 100.0% |
| Bactiguard Holding AB (publ) | 233.09 Million SEK | 100.0% |
| BICO Group AB (publ) | 1.85 Billion SEK | 100.0% |
| Boule Diagnostics AB (publ) | 166.1 Million SEK | 100.0% |
| CellaVision AB (publ) | 64.7 Million SEK | 100.0% |
| Clinical Laserthermia Systems AB (publ) | 454 Thousand SEK | 100.0% |
| Chordate Medical Holding AB (publ) | - SEK | NaN% |
| C-Rad AB (publ) | 1.8 Million SEK | 100.0% |
| Duearity AB (publ) | 10.58 Million SEK | 100.0% |
| Dignitana AB (publ) | 19.1 Million SEK | 100.0% |
| Episurf Medical AB (publ) | 5.2 Million SEK | 100.0% |
| Getinge AB (publ) | 8.07 Billion SEK | 100.0% |
| Scandinavian Real Heart AB (Publ) | 8.24 Million SEK | 100.0% |
| Iconovo AB (publ) | 7.72 Million SEK | 100.0% |
| Integrum AB (publ) | 6.42 Million SEK | 100.0% |
| Luxbright AB (publ) | 206.02 Thousand SEK | 100.0% |
| Mentice AB (publ) | 9.55 Million SEK | 100.0% |
| OssDsign AB (publ) | 3.15 Million SEK | 100.0% |
| Paxman AB (publ) | 13.57 Million SEK | 100.0% |
| Promimic AB (publ) | - SEK | NaN% |
| Qlife Holding AB (publ) | 20.73 Million SEK | 100.0% |
| SciBase Holding AB (publ) | 6.79 Million SEK | 100.0% |
| ScandiDos AB (publ) | - SEK | NaN% |
| Sectra AB (publ) | 31.78 Million SEK | 100.0% |
| Sedana Medical AB (publ) | 4.3 Million SEK | 100.0% |
| Senzime AB (publ) | 11.46 Million SEK | 100.0% |
| SpectraCure AB (publ) | 6.71 Million SEK | 100.0% |
| Stille AB | 62.94 Million SEK | 100.0% |
| Vitrolife AB (publ) | 2.08 Billion SEK | 100.0% |
| Xvivo Perfusion AB (publ) | 31.43 Million SEK | 100.0% |